- Home
- STGW vs ATAI Comparison
STGW vs ATAI Comparison
Compare STGW & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | STGW | ATAI |
|---|---|---|
| Founded | 1980 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.4B |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | STGW | ATAI |
|---|---|---|
| Price | $6.22 | $3.93 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 7 |
| Target Price | $8.46 | ★ $13.86 |
| AVG Volume (30 Days) | 2.1M | ★ 4.1M |
| Earning Date | 02-26-2026 | 03-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1954.71 | N/A |
| EPS | ★ 0.06 | N/A |
| Revenue | ★ $2,890,264,000.00 | $3,018,000.00 |
| Revenue This Year | $4.67 | $962.66 |
| Revenue Next Year | $8.98 | N/A |
| P/E Ratio | $112.85 | ★ N/A |
| Revenue Growth | 6.75 | ★ 811.78 |
| 52 Week Low | $4.03 | $1.15 |
| 52 Week High | $7.48 | $6.75 |
Technical Indicators
Market Signals| Indicator | STGW | ATAI |
|---|---|---|
| Relative Strength Index (RSI) | 58.66 | 48.89 |
| Support Level | $4.80 | $3.83 |
| Resistance Level | $7.17 | $4.17 |
| Average True Range (ATR) | 0.43 | 0.21 |
| MACD | 0.10 | 0.04 |
| Stochastic Oscillator | 60.47 | 64.94 |
Price Performance
Historical ComparisonAbout STGW Stagwell Inc.
Stagwell Inc is the challenger holding company built to transform marketing. It delivers scaled creative performance for the world's ambitious brands, connecting culture-moving creativity with a technology to harmonize the art and science of marketing. The company's segments include Integrated Agencies Network; Brand Performance Network; and Communications Network. It generates maximum revenue from the Integrated Agencies Network segment. Geographically, it derives a majority of its revenue from the United States.
About ATAI ATAI Life Sciences N.V.
Atai Beckley NV is a clinical-stage biopharmaceutical company. It aims to develop mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 and BPL-003 for the treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder.